BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its financial results for the first half of 2025 and provides a business update. Pier Vincenzo Piazza, CEO of Aelis Farma, stated: “The first half of 2025 was characterized by important achievements in the development of our drug